Rexahn has established a huge pipeline of oncology drugs that may change the way cancers are treated in the future. There is a variety of compounds to limit the risk profile of the company, and allow investors to establish some type of speculative position. We see potential upside of at least 300% rise in share price in the coming year.
There are many biotechs out there that attempt to create new molecules for the treatment of today's deadliest forms of cancer. With the speculative nature of these oncology biotechs brings some massive speculation with overblown share prices. Despite this there is one company that has been undervalued in the oncology space for the longest time trading currently at $0.43 per...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|